Enhancement of natural killer cell activity in HIV-1-infected subjects by a mixture of the calcium ionophore A23187 and the phorbol ester tea: Lack of response to a similar challenge with interleukin-2 or α-interferon

American Journal of Therapeutics

Volumn 4, Issue 11-12, 1997, Pages 413-421

  Sepúlveda, Cecilia ^a   Puente, Javier ^b   Weinstein, Caroline ^b   Wolf, Marion E ^c   Mosnaim, Aron D ^d,e  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

^d The Chicago Medical College   (United States)

^e ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

Acquired immunodeficiency syndrome; Calcium ionophore A23187; Human immunodeficiency virus type 1; Interleukin 2; Natural killer cell activity; Phorbol ester TPA; interferon

Indexed keywords

CALCIMYCIN; PHORBOL 13 ACETATE 12 MYRISTATE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT INTERLEUKIN 2;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLYSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; VIRUS INFECTION;

EID: 0030694527     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199711000-00013     Document Type: Article

References (46)

1. World Health Organization: Global Programme on AIDS. The HIV/AIDS pandemic: overview, 1994.
2. Comision Nacional del Sida, Chile, Ministerio de Salud: Informe de la Situación Epidemiológica de las Epidemia VIH/SIDA en Chile, December 31, 1995.
3. Fahey J, Taylor J, Detels R, et al: The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type-1. N Engl J Med 1990;322: 166-172.
4. + lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review. J Infect Dis 1992;165:352-363.
5. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989;47:187-376.
6. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH: The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T-lymphocytes. J Immunol 1986;136:4480-4486.
7. Ritz J, Schmidt RE, Michon J, Hercend T, Schlossman SF: Characterization of functional surface structures on human killer cells. Adv Immunol 1988;42:181-211.
8. Creemers PC, Stark DF, Boyko WJ: Evaluation of natural killer cell activity in patients with persistent generalized lymphadenopathy and acquired immunodeficiency syndrome. Clin Immunol Immunopathol 1985;36:141-50.
9. Katz JD, Mitsuyasu R, Gottlieb MS, Lebow LT, Bonavida B: Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. II. Normal antibody-dependent cellular cytotoxicity (ADCC) mediated by effector cells defective in natural killer (NK) cytotoxicity. J Immunol 1987;139:55-60.
10. - subset. AIDS Res Hum Retrovir 1990;6:1451-1457.
11. London L, Perussia B, Trinchieri G: Induction of proliferation in vitro of resting human natural killer cells: IL-2 induces into cell cycle most peripheral blood NK cells but only a minor subset of low density T cells. J Immunol 1986;137:3845-3854.
12. Whiteside TL: Natural killer activity in the diagnosis of immune disfunction. Clin Immunol 1991;11:27-31.
13. Puente J, Maturana P, Miranda D, Navarro C, Wolf ME, Mosnaim AD: Enhancement of human natural killer activity by opioid peptides: response to methionine-enkephalin and B-endorphin. Brain Behav Immun 1992; 6:32-39.
14. Puente J, Diaz M, Salas MA, et al: Studies of natural killer cell activity in a drug-free, healthy population. Response to a challenge with taxol, estramustine and lipopolysaccharide. Int J Clin Pharmacol Ther Toxicol 1995; 33:457-461.
15. Mosnaim AD, Wolf ME, Maturana P, et al: In vitro studies of natural killer cell activity in post traumatic stress disorder patients. Response to methionine-enkephalin challenge. Immunopharmacology 1993;25:107-116.
16. Mosnaim AD, Wolf ME, Maturana P, Puente J, Freitag F, Diamond S: In vitro studies of natural killer cell activity in migraineurs: changes in response to methionine-enkephalin challenge during a migraine episode. Headache Quarterly, Current Treatment and Research 1993; 4:36-41.
17. Mosnaim AD, Wolf ME, Maturana P, Puente J, Freitag F, Diamond S: In vitro studies of natural killer cell activity in migraineurs: changes in response to a B-endorphin challenge during a migraine episode. Headache Quarterly, Current Treatment and Research 1994;5:142-148.
18. Naume B, Espevik T: Immunoregulatory effects of cytokines on natural killer cells. Scand J Immunol 1994;40: 128-134.
19. Faist E, Schinkel C, Zimmer S, Kremer JP, Donnersmarck G, Schildberg G: Inadequate interleukin-2 synthesis and interleukin-2 messenger expression following thermal and mechanical trauma in humans is caused by defective transmembrane signaling. J Trauma 1993;34:846-854.
20. Puente J, Carvajal T, Parra S, et al: Enhancement of natural killer cell activity in septic shock patients by a mixture of the calcium ionophore A23187 and the phorbol ester TPA: in vitro studies. Int J Clin Pharmacol Ther Toxicol 1994;32:19-23.
21. Vély F, Vivier E: Mécanismes moléculaires de la cytotoxicité des cellules NK. Médicine/Sciences 1996;44:458-464.
22. Jondal M, Ng J, Maj-Britt A: A direct induction of lymphocytes killing by Ca ionophore and phorbol ester treatment. Cell Immunol 1987;105:23-32.
23. Windebank K, Abraham R, Powis G, Olsen R, Barna T, Leibson P: Signal transduction during human natural killer cell activation: inositol phosphate generation and regulation by cyclic AMP. J Immunol 1988;141:3951-3957.
24. Puente J, Salas M, Cañon C, Miranda D, Wolf ME, Mosnaim AD: Activation of protein tyrosine kinase: a possible requirement for fixed bacteria and lipopolysaccharide-induced increase in human natural killer cell activity. Int J Clin Pharmacol Ther Toxicol 1996;34:212-218.
25. Centers for Disease Control: Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987;36:1-15.
26. Landay A, Muirhead K: Procedural guidelines for performing immunophenotyping by flow cytometry. Clin Immunol Immunopathol 1989;52:48-60.
27. Puente J, Miranda D, Gaggero A, et al: Defecto immunológico en el shock séptico. Deficiencia de células natural killer y de linfocitos. T Rev Méd Chile 1991;119:142-146.
28. Maturana P, Puente J, Miranda D, Sepúlveda C, Wolf ME, Mosnaim AD: Natural killer cell activity in patients with septic schock. J Crit Care 1991;6:42-45.
29. Bender BS, Chrest FJ, Adler WH: Phenotypic expression of natural killer cells associated membrane antigens and cytolitic function of peripheral blood cells from different aged humans. J Clin Immunol 1986;21:31-36.
30. Puente J, Carvajal T, Parra S, et al: In vitro studies of natural killer cell activity in septic shock patients. Response to a challenge with α-interferon and interleukin-2. Int J Clin Phar Thermacol Toxicol 1993;31:271-275.
31. Bender BS, Winchurch RA, Thupari JN, Proust JJ, Adler WH, Munster AM: Depressed natural killer cell function in thermally injured adults: successful in vivo and in vitro immunomodulation and the role of endotoxin. Clin Exp Immunol 1988;71:120-125.
32. Chatila T, Wong R, Young M, Miller R, Terhorst C, Geha R: An immunodeficiency characterized by defective signal transduction in T lymphocytes. N Engl J Med 1989; 320:696-702.
33. Gibboney JJ, Shenoy A, Jin X, Brahmi Z: Signal transduction in activated natural killer cells and natural killer cells inactivated with sensitive targets. Nat Immun 1992; 11:57-58.
34. Lyunggren K, Karlson A, Fenjö EM, Jondal M: Natural and antibody-dependent cytotoxicity in different clinical stages of human immunodeficiency virus type-I infection. Clin Exp Immunol 1989;75:184-189.
35. Sirienni MC, Tagliaferri F, Aiuti F: Pathogenesis of the natural killer cell deficiency in AIDS. Immunol Today 1990;11:81-82.
36. + and declining CD3 populations suggest regulatory responses linked to loss of CD4 lymphocytes. J Acquir Immune Defic Syndr 1993;6:153.
37. + natural killer subset during HIV infection. Cytometry 1995;22:10-15.
38. Siegel JP, Sharon M, Smith P, Leonard W: The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities. Science 1987;238: 75-78.
39. Voss S, Sondel P, Robb RJ: Characterization of the interleukin-2 receptors (IL2R) expressed on human natural killer cells activated in vivo by IL-2: association of the p64 IL2R gamma chain with the IL2R beta chain in functional intermediate-affinity IL2R. J Exp Med 1992;176: 531-541.
40. Whiteside TL, Herberman R: Characteristics of natural killer cells and lymphokine-activated killer cells. Immunol Allergy Clin 1990;10:663-704.
41. Bernstein ZP, Porter MM, Gould M: Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity. Blood 1995;86:3287-3294.
42. Atkinson EA, Gerrard JM, Hildes GE, Greenberg AH: Studies of the mechanism of natural killer (NK) degranulation and cytotoxicity. J Leukocyte Biol 1990;47: 39-48.
43. Bonnema JD, Karnitz LM, Schoon RA, Abraham R, Leibson P: Fc receptor stimulation of phosphatidylinositol 3-kinase in natural killer cells is associated with protein kinase C-independent granule release and cell mediated cytotoxicity. J Exp Med 1994;180:1427-1435.
44. Cauda R, Tumbarello M, Ortona L, Kanda P, Kennedy RC, Chanh TC: Inhibition of normal human natural killer cell activity by human immunodeficiency virus synthetic transmembrane peptides. Cell Immunol 1988; 115:57.
45. Reddy MM, Chinoy P, Grieco MH: Differential effects of α-interferon and interleukin-2 on natural killer cell activity in patients with acquired immune deficiency syndrome. J Biol Response Modif 1984;3:379.
46. Chehimi J, Starr SE, Frank I, et al: Natural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients. J Exp Med 1992;175:780-796.